AACR 2021: TNFR2 and PD-1/PD-L1/TNFR2 humanized mice aid exploration of combination strategies to overcome tumor immune escape mechanisms
HomeNews & ResourcesPostersAACR 2021: TNFR2 and PD-1/PD-L1/TNFR2 humanized mice aid exploration of combination strategies to overcome tumor immune escape mechanisms
AACR 2021: TNFR2 and PD-1/PD-L1/TNFR2 humanized mice aid exploration of combination strategies to overcome tumor immune escape mechanisms
TNF signaling via TNFR2 plays an important role in modulation of the immune system via pro- and anti-inflammatory activities of T cells.
Biocytogen has generated a humanized B-hTNFR2 and a humanized B-hPD-1/hPD-L1/hTNFR2 mouse model to evaluate in vivo efficacy of TNFR2 antibodies.
Anti-human TNFR2 antibodies inhibited MC38 tumor growth in B-hTNFR2 mice.
B-hTNFR2 and B-hPD-1/hPD-L1/hTNFR2 mice are useful models to explore anti-PD-1, anti-PD-L1, and anti-TNFR2 combination therapy strategies, with promising activity and low cytotoxicity.
Share:
We use cookies to personalize content, analyze traffic, and ensure that we give you the best experience on our website. Click To Continue